Conflicting results from clinical observations and murine models: What is the role of plasminogen activators in tumor growth?

Journal of the National Cancer Institute

Volumn 98, Issue 11, 2006, Pages 726-727

  Narazaki, Masashi ^a   Tosato, Giovanna ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; ENDOSTATIN; FIBRONECTIN; LAMININ; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PLASMINOGEN ACTIVATOR; TANOMASTAT; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; ANTINEOPLASTIC AGENT; CATHEPSIN; ENZYME INHIBITOR; ORGANIC COMPOUND; PLASMINOGEN ACTIVATOR INHIBITOR; TUMOR MARKER;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; EDITORIAL; GENE OVEREXPRESSION; HUMAN; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; METABOLISM; NEOPLASM; NOTE; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; TREATMENT FAILURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CATHEPSINS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; MATRIX METALLOPROTEINASES; MICE; NEOPLASMS; ORGANIC CHEMICALS; PLASMINOGEN ACTIVATORS; PLASMINOGEN INACTIVATORS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TISSUE INHIBITOR OF METALLOPROTEINASES; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 33745279426     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj227     Document Type: Editorial

References (28)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-9.
3. Decock J, Paridaens R, Cufer T. Proteases and metastasis: Clinical relevance nowadays? Curr Opin Oncol 2005;17:545-50.
4. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005;9:267-85.
5. Bergers G, Coussens LM. Extrinsic regulators of epithelial tumor progression: Metalloproteinases. Curr Opin Genet Dev 2000;10:120-7.
6. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
7. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 2000;18:1135-49.
8. Wang CS, Wu TL, Tsao KC, Sun CF. Serum TIMP-1 in gastric cancer patients: A potential prognostic biomarker. Ann Clin Lab Sci 2006; 36:23-30.
9. Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai FY, et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 2004;5:443-53.
10. Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001;93:913-20.
11. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002;94:116-28.
12. Weigelt B, Peterse JL, van't Veer LJ. Breast cancer metastasis: Markers and models. Nat Rev Cancer 2005;5:591-602.
13. Choong PF, Nadesapillai AP. Urokinase plasminogen activator system: A multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res 2003:S46-58.
14. Duffy MJ, Duggan C. The urokinase plasminogen activator system: A rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 2004;37:541-8.
15. de Bock CE, Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev 2004; 24:13-39.
16. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1981;41:4629-36.
17. Merchan JR, Tang J, Hu G, Lin Y, Mutter W, Tong C, et al. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. J Natl Cancer Inst 2006;98:756-64.
18. Pepper MS, Montesano R. Proteolytic balance and capillary morphogenesis. Cell Differ Dev 1990;32:319-27.
19. Bajou K, Maillard C, Jost M, Lijnen RH, Gils A, Declerck P, et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 2004;23:6986-90.
20. Frandsen TL, Holst-Hansen C, Nielsen BS, Christensen IJ, Nyengaard JR, Carmeliet P, et al. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model. Cancer Res 2001;61:532-7.
21. Pupa SM, Menard S, Forti S, Tagliabue E. New insights into the role of extracellular matrix during tumor onset and progression. J Cell Physiol 2002;192:259-67.
22. Engbring JA, Kleinman HK. The basement membrane matrix in malignancy. J Pathol 2003;200:465-70.
23. Nielsen BS, Sehested M, Duun S, Rank F, Timshel S, Rygaard J, et al. Uro-kinase plasminogen activator is localized in stromal cells in ductal breast cancer. Lab Invest 2001;81:1485-501.
24. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 2002;295:2387-92.
25. Overall CM, Kleifeld O. Tumour microenvironment - opinion: Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006;6:227-39.
26. Witty JP, Lempka T, Coffey RJ Jr, Matrisian LM. Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. Cancer Res 1995;55:1401-6.
27. Balbin M, Fueyo A, Tester AM, Pendas AM, Pitiot AS, Astudillo A, et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 2003;35:252-7.
28. Fingleton B. Matrix metalloproteinase inhibitors for cancer therapy: The current situation and future prospects. Expert Opin Ther Targets 2003;7:385-97.